Safety Of Dostarlimab In Combination With Chemotherapy In Patients With Primary Advanced Or Recurrent Endometrial Cancer In A Phase 3, Randomized, Placebo-Controlled Trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

MIRASOL Trial: Efficacy Of Mirvetuximab Soravtansine In Folate Receptor Alpha High, Platinum Resistant Ovarian Cancer By Type And Number Of Prior Treatment Regimes: An Exploratory Analysis.

Initial Efficacy And Safety Results From ENGOT-Ov60/GOG-3052/RAMP 201: A Phase 2 Study Of Avutometinib (VS-6766) ± Defactinib In Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

SHAPE Trial: An International Randomized Phase III Trial Comparing Radical Hysterectomy And Pelvic Node Dissection (RH) Vs Simple Hysterectomy And Pelvic Node Dissection (SH) In Patients With Low-Risk Early-Stage Cervical Cancer (LRESCC)

Durvalumab With Paclitaxel/Carboplatin + Bevacizumab Then Maintenance Durvalumab, Bevacizumab + Olaparib In Patients With Newly Diagnosed Advanced Ovarian Cancer Without A Tumour BRCA1/2 Mutation: Results From The DUO-O/ENGOT-Ov46/AGO-OVAR 23/GOG-3025 Trial

First Interim Analysis Of The SCOUT-1 Study (NOGGO Ov54, NCT04830709): A Non-Interventional Study To Evaluate Treatment Patterns And Longterm Outcome In Patients With Newly Diagnosed Advances Ovarian Cancer.

Molecular Alterations Predictive Of Outcome In Early Staged Cervical Cancer : A Translational Investigation From The SENTICOL III Trial

Trial In Progress: A Phase 2/3 Study Of Navtemadlin As Maintenance Therapy In Patients With Advanced Or Recurrent Endometrial Cancer (EC) Who Responded To Chemotherapy (ENGOT-En21 And GOG-3089)

A Phase II, Multicentre, Open-Label Study Of Abemaciclib And Letrozole In Patients With Estrogen Receptor-Positive Rare Ovarian Cancer

ROSELLA (GOG-3073, ENGOT-Ov72/MITO): A Phase 3 Study Of Relacorilant + Nab-Paclitaxel Vs. Nab-Paclitaxel In Advanced, Platinum-Resistant Ovarian Cancer

AGO-OVAR 28 / ENGOT-Ov57: Niraparib Vs Niraparib In Combination With Bevacizumab In Patients With Carboplatin-Taxane Based Chemotherapy In Advanced Ovarian Cancer (A Multicentre Randomised Phase III Trial)

ENGOT-EN20/GOG-3083/XPORT-EC-042 A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA

ARTISTRY-7: A Phase 3, Multicenter Study Of Nemvaleukin Alfa In Combination With Pembrolizumab Versus Chemotherapy In Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (GOG-3063; ENGOT-OV68)

A Phase 2 Study (GOG-3084) Of ADP-A2M4CD8 TCR T-Cell Therapy, Alone Or In Combination With Nivolumab, In Patients With Recurrent Ovarian Cancers

Long-Term Follow Up Of Selinexor Maintenance For Patients With TP53wt Advanced Or Recurrent Endometrial Cancer: A Pre-Specified Subgroup Analysis From The Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study